Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

More documents

Recommendations

Info

Our new R&D model: Paradigm changes Genentech offer – Development perspective Franchises and assets Summary 10
<strong>Roche</strong> <strong>Pharma</strong> pipeline overview Focused on five Disease Biology Areas Oncology Xeloda MabThera Herceptin Avastin Tarceva Pertuzumab T-DM1 R1507 (IGF-1R mAb) Apomab Apo2L/TRAIL Anti-CD40 mAb Hedgehog antagonist 18 phase I compounds On Hand RA/Inflammation MabThera Actemra R1594 ocrelizumab R667 RARg 9 phase I compounds Metabolic R1658 CETP Inh. R1583 GLP-1 R1439 dual PPAR 9 phase I compounds Promising Late Stage Virology Pegasys Tamiflu R3484 HPV16 R1626 HCV pol. Inh. R7128 HCV pol. Inh. R7227 HCV prot. inh. Emerging Mid-Term CNS ocrelizumab RRMS R1678 Schizophrenia R3487 Alzheimer’s 3 phase I compounds Early Stage 11
Page 1 and 2: Clinical Development at Roche: Driv
Page 3 and 4: Our new R&D model: Paradigm changes
Page 5 and 6: Biomarkers A central element throug
Page 7 and 8: Our new R&D model: Paradigm changes
Page 9: Enhance innovation …by maintainin
Page 13 and 14: Major Roche-managed oncology submis
Page 15 and 16: Avastin and cetuximab in combinatio
Page 17 and 18: Avastin and cetuximab in combinatio
Page 19 and 20: Attacking the HER2 pathway from mul
Page 21 and 22: Implementing biomarker strategy for
Page 23 and 24: Key drivers for long term developme
Page 25 and 26: Actemra: The first IL-6 receptor in
Page 27 and 28: CETP Inhibitor R1658 is a unique CE
Page 29 and 30: Taspoglutide: investigational once-
Page 31 and 32: CD20 targeting: new treatment strat
Page 33 and 34: Roche R&D opportunities in summary
Page 35 and 36: Avastin’s position as standard of

Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?